Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)
Technology appraisal
Reference number: TA879
Published:
Tools and resources
Tools and resources to help you put the guidance into practice.